Pope Leo early-stage adenocarcinoma is a reminder that lung nodules often cause no symptoms and that people who never smoked can get lung cancer.
News|Articles|January 2, 2025
Top 5 Biologics Articles of 2024
Author(s)MHE Staff
Check out this list of the top five biologics articles posted on Managed Healthcare Executive this year!
Advertisement
1. 2024 Formulary Moves
The large pharmacy benefit managers have switched up their coverage of biosimilars, especially the biosimilars to Humira (adalimumab).
2. PBMs Start to Embrace Biosimilars
Pharmacy benefit managers (PBMs) are slowly coming around and putting biosimilars on their formularies. IQVIA estimates that the dearth of a Humira (adalimumab) biosimilars last year cost patients and employers cumulatively $6 billion.
3. Prolia and Xgeva Biosimilar Companies Are Queuing Up
But Amgen and Sandoz are in a patent fight over the launching of Sandoz's biosimilars to the bone-building drugs.
4. Biologics that Treat Arthritis May Lower Cardiovascular Risk
A recent study has found that biologics may have an effect on arterial wall inflammation and plaque composition, which offsets the influence of joint-derived inflammation in patients with arthritis.
5. New Biosimilars Continue to be Approved But Uptake Varies by Class
A recent IQVIA report found that uptake of biosimilars on the market for at least three years varies from 8% for insulin lispro to 82% for bevacizumab.
Advertisement
Related to this article
Young-onset lung cancer often strikes nonsmokers, and current screening based on smoking is not likely to find it, says Singhi, an assistant professor at UT MD Anderson Cancer Center in Houston. New risk-based screening, liquid biopsies, and breath tests aim earlier detection.
Rex Hoffman, M.D., MBA, says physician shortages and burnout are the most underestimated pressures on health system.
Rex Hoffman, M.D., MBA, of Providence Holy Cross walks through a CMO’s day in a hospital that often runs 85% to 100% full, from safety huddles to discharges.
On average, caregivers want to see their children with ADHD fall asleep 30 minutes faster, but the best sleep treatments average approximately 20 minutes, a new survey study found.
Research findings presented at CHEST meeting show COPD hospital readmission drops with discharge checklists and navigation. Other research suggests targeting readmission prevention efforts on patents discharged to post-acute facilities.
As the pharmacist pipeline tightens, leaders from UC Davis Health, UCSF Health, and Sutter Health say financial sustainability now depends as much on capacity as on cost.
GLP-1 use in adults 65 and older with MASLD was linked to a 45% lower risk of death, and a 28% lower risk of hepatic decompensation, a new Houston Methodist Research Institute study shows.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Rex Hoffman, M.D., on physician burnout and collaborative leadership | HSES 2026
2
GLP-1 therapy tied to lower mortality and liver decompensation in older adults with MASLD
3
Preventing hospital readmissions among patients with COPD. Here are some ideas on how to do that | CHEST 2026
4
Algia Pharma completes investigational drug toxicology study for non-opioid acute pain regimen AlgiaPak
5